Adrenergics is developing novel therapeutics to treat dilated cardiomyopathy (DCM) in patients that do not respond to existing therapies. The company focuses on a key disease driver to develop medicines that are expected to modulate disease progression leading to improved outcomes in this difficult-to-treat patient population.